" class="no-js "lang="en-US"> Qurient Announces Clinical Study for Solid Tumors Treatments
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors | PTF

January 31 2023

Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors

Qurient, a clinical-stage biotech company based in Korea, has announced that the first patient has been dosed in the Phase 1b/2 clinical study of Q702 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with Solid Tumors.

The Q702 Phase 1b/2 study (NCT05438420) is being conducted at seven investigative sites in the U.S. and Korea, and approximately 142 patients with advanced solid tumors are scheduled to be enrolled. The primary objectives of the Phase 1b/2 study are to determine the safety and efficacy of Q702 in combination with KEYTRUDA in study subjects with advanced solid cancers.

“We are pleased to initiate evaluation of Q702 in combination with KEYTRUDA for the treatment of esophageal, gastric, hepatocellular, and cervical cancers, where limited immuno-oncology treatment options are currently available,” said Kiyean Nam, Ph.D., CEO of Qurient. “We have previously shown the potential additive benefit of Q702 in combination with anti-PD-1 therapy in preclinical models, and we expect the same clinical benefits of Q702 in combination with KEYTRUDA for patients.”

  1. Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

    Appointments

     Read more
  2. Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

    Clinical Trials

     Read more
  3. BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

    News

     Read more
  4. Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution

    Fundraising

     Read more
  5. GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

    Diseases

     Read more
More On